Manfred Groeppel

Statistics

Publications

Citations

122

H-Index

Active since

2010

Affiliations

Max Planck Institute of Biochemistry(Current)

Manfred Groeppel is an author at Max Planck Institute of Biochemistry specializing in pharmacology, dihydroorotate dehydrogenase inhibitors, and safety profile characterization.

Publications per year

2010–2020

Publications

4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease†

Leo R. Fitzpatrick, Ludwig Deml, Claudia Hofmann et al. · Inflammatory Bowel Diseases · 2010 · 66 citations · Full text

Medicine, Immunology, Pharmacology +17

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study

Andreas Muehler, Hella Kohlhof, Manfred Groeppel et al. · Drugs in R&D · 2019 · 29 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects

Andreas Muehler, Hella Kohlhof, Manfred Groeppel et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2020 · 27 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

1–3 of 3